Share Price and Basic Stock Data
Last Updated: February 10, 2026, 10:28 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gayatri BioOrganics Ltd operates in the chemicals sector, specifically focusing on organic cellulose derivatives. The company has faced significant fluctuations in revenue, with its sales reporting a mere ₹1.67 lakh in March 2023, following a complete absence of revenue in the previous two fiscal years. This decline in operational activity raises concerns about the sustainability of the business model. The company’s market capitalization stood at ₹113 Cr, reflecting a challenging environment for growth. With reported sales of ₹0.00 across several quarters post-March 2023, it indicates a persistent struggle to generate consistent revenue streams. The absence of a stable sales base raises questions about the company’s operational viability and strategic direction in the competitive chemicals sector, which typically expects more robust financial performance. The company’s ability to pivot and innovate in product offerings will be critical to reversing this trend and restoring investor confidence.
Profitability and Efficiency Metrics
Profitability metrics for Gayatri BioOrganics Ltd reveal a concerning trend, with the company recording a net profit of -₹0.80 Cr for the fiscal year ending March 2023. The operating profit margin (OPM) stood at -46.11%, indicating substantial inefficiencies in cost management. Furthermore, the interest coverage ratio (ICR) was reported at -1.62, suggesting that the firm is unable to cover its interest obligations from operating income. This situation is compounded by the company’s negative return on capital employed (ROCE) of -54.61% for the same period, reflecting the ineffective use of capital in generating profits. The ongoing operational losses, combined with rising expenses, particularly in the March 2023 quarter where expenses totaled ₹2.44 Cr against minimal sales, emphasize the urgent need for operational restructuring and cost control measures to enhance profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Gayatri BioOrganics Ltd shows a precarious financial position, with total borrowings amounting to ₹37.29 Cr against reserves of -₹115.16 Cr, indicating a negative net worth scenario. This negative reserve situation poses significant risks to creditors and shareholders alike. The company’s current ratio stands at a mere 0.04, reflecting severe liquidity issues as it struggles to meet short-term liabilities, which can hinder operational continuity. Additionally, the price-to-book value ratio (P/BV) of -1.50x further underscores the market’s negative perception of the company’s equity value. The total debt-to-equity ratio of -1.03 raises alarms regarding financial leverage, indicating that the company has more debt than equity, further complicating its financial health. The combination of these factors suggests that Gayatri BioOrganics Ltd must focus on deleveraging and improving its balance sheet before it can consider growth opportunities.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Gayatri BioOrganics Ltd indicates a significant shift in ownership dynamics, with promoters holding only 21.59% as of March 2025, down from 40.63% in earlier months. This reduction in promoter holding could signal a lack of confidence in the company’s future prospects, which could deter potential investors. The public holds a substantial 77.76% stake, hinting at considerable retail participation, yet the low foreign institutional investment (FII) at 0.01% suggests limited institutional confidence. Domestic institutional investors (DIIs) account for 0.65%, which is relatively low compared to industry norms, indicating hesitance among institutional players to back the company amid ongoing financial challenges. The total number of shareholders stood at 31,471, suggesting a broad base of retail investors, but the declining promoter stake may raise concerns about the alignment of interests moving forward.
Outlook, Risks, and Final Insight
The outlook for Gayatri BioOrganics Ltd remains uncertain, primarily due to its negative profitability trends, high operational costs, and significant liquidity challenges. The company faces risks related to its ability to generate consistent revenue, manage its debt levels, and restore investor confidence in a competitive chemicals landscape. Potential turnaround strategies could include focusing on operational efficiencies, exploring new market opportunities, and restructuring its financial obligations to improve liquidity. However, without a clear path to profitability, the risk of further financial deterioration looms large. Investors should remain cautious, given the company’s historical performance and current financial metrics, while closely monitoring any strategic initiatives that may emerge in the coming quarters to turn around its fortunes.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gayatri BioOrganics Ltd | 113 Cr. | 14.3 | 20.0/5.35 | 4.62 | 0.00 % | 40.7 % | % | 10.0 | |
| Industry Average | 113.00 Cr | 14.30 | 0 | 4.62 | 0.00% | 40.70% | 0% | 10.00 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 1.67 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.24 | 0.12 | 2.31 | 0.18 | 0.07 | 0.10 | 0.18 | 0.15 | 0.11 | 0.08 | 0.10 | 0.18 | 0.12 |
| Operating Profit | -0.24 | -0.12 | -0.64 | -0.18 | -0.07 | -0.10 | -0.18 | -0.15 | -0.11 | -0.08 | -0.10 | -0.18 | -0.12 |
| OPM % | -38.32% | ||||||||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.03 | 0.02 | 0.04 | 0.04 | 0.05 | 0.06 | 0.07 | 0.08 | 0.07 | 0.08 | 0.09 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.24 | -0.12 | -0.67 | -0.20 | -0.11 | -0.14 | -0.23 | -0.21 | -0.18 | -0.16 | -0.17 | -0.26 | -0.21 |
| Tax % | 87.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.45 | -0.12 | -0.67 | -0.20 | -0.11 | -0.14 | -0.23 | -0.21 | -0.18 | -0.16 | -0.17 | -0.26 | -0.21 |
| EPS in Rs | -0.06 | -0.02 | -0.09 | -0.03 | -0.01 | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 | -0.02 | -0.03 | -0.03 |
Last Updated: February 1, 2026, 8:46 pm
Below is a detailed analysis of the quarterly data for Gayatri BioOrganics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Expenses, as of Sep 2025, the value is 0.12 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.18 Cr. (Jun 2025) to 0.12 Cr., marking a decrease of 0.06 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.12 Cr.. The value appears strong and on an upward trend. It has increased from -0.18 Cr. (Jun 2025) to -0.12 Cr., marking an increase of 0.06 Cr..
- For OPM %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Interest, as of Sep 2025, the value is 0.09 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.08 Cr. (Jun 2025) to 0.09 Cr., marking an increase of 0.01 Cr..
- For Depreciation, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.21 Cr.. The value appears strong and on an upward trend. It has increased from -0.26 Cr. (Jun 2025) to -0.21 Cr., marking an increase of 0.05 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is -0.21 Cr.. The value appears strong and on an upward trend. It has increased from -0.26 Cr. (Jun 2025) to -0.21 Cr., marking an increase of 0.05 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.03. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded -0.03.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 213.97 | 255.89 | 137.22 | 79.32 | 173.32 | 155.48 | 0.00 | 0.00 | 0.00 | 1.67 | 0.00 | 0.00 | 0.00 |
| Expenses | 201.10 | 240.58 | 162.03 | 128.53 | 197.18 | 159.09 | 0.61 | 0.50 | 0.50 | 2.44 | 0.53 | 0.45 | 0.48 |
| Operating Profit | 12.87 | 15.31 | -24.81 | -49.21 | -23.86 | -3.61 | -0.61 | -0.50 | -0.50 | -0.77 | -0.53 | -0.45 | -0.48 |
| OPM % | 6.01% | 5.98% | -18.08% | -62.04% | -13.77% | -2.32% | -46.11% | ||||||
| Other Income | 0.30 | 1.27 | 0.96 | -16.53 | 11.87 | 2.10 | 85.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 7.57 | 9.39 | 12.74 | 11.57 | 0.19 | 4.71 | 0.01 | 0.00 | 0.00 | 0.03 | 0.15 | 0.28 | 0.32 |
| Depreciation | 4.25 | 2.37 | 2.13 | 5.34 | 6.96 | 9.29 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 1.35 | 4.82 | -38.72 | -82.65 | -19.14 | -15.51 | 84.47 | -0.50 | -0.50 | -0.80 | -0.68 | -0.73 | -0.80 |
| Tax % | 0.00% | 18.26% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 26.25% | 0.00% | 0.00% | |
| Net Profit | 1.35 | 3.93 | -38.73 | -82.65 | -19.14 | -15.51 | 84.47 | -0.50 | -0.50 | -1.01 | -0.68 | -0.73 | -0.80 |
| EPS in Rs | 0.27 | 0.77 | -6.27 | -10.49 | -2.43 | -1.97 | 10.72 | -0.06 | -0.06 | -0.13 | -0.09 | -0.09 | -0.10 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 191.11% | -1085.50% | -113.40% | 76.84% | 18.97% | 644.62% | -100.59% | 0.00% | -102.00% | 32.67% | -7.35% |
| Change in YoY Net Profit Growth (%) | 0.00% | -1276.61% | 972.10% | 190.24% | -57.88% | 625.65% | -745.21% | 100.59% | -102.00% | 134.67% | -40.03% |
Gayatri BioOrganics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -8% |
| 3 Years: | -19% |
| TTM: | -12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 18% |
| 3 Years: | 3% |
| 1 Year: | 103% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Last Updated: September 5, 2025, 3:31 pm
Balance Sheet
Last Updated: December 4, 2025, 2:56 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 50.92 | 50.92 | 61.78 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 |
| Reserves | -44.79 | -40.86 | -79.58 | -159.93 | -181.20 | -195.74 | -111.27 | -111.77 | -112.26 | -113.27 | -113.95 | -114.68 | -115.16 |
| Borrowings | 75.47 | 88.12 | 115.50 | 35.11 | 35.11 | 35.11 | 35.11 | 35.11 | 35.11 | 35.66 | 36.36 | 36.90 | 37.29 |
| Other Liabilities | 94.72 | 43.94 | 44.00 | 150.81 | 212.77 | 226.93 | 0.46 | 0.47 | 0.60 | 0.44 | 0.37 | 0.66 | 0.75 |
| Total Liabilities | 176.32 | 142.12 | 141.70 | 104.78 | 145.47 | 145.09 | 3.09 | 2.60 | 2.24 | 1.62 | 1.57 | 1.67 | 1.67 |
| Fixed Assets | 48.88 | 47.19 | 45.69 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.37 | 5.80 | 6.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 127.07 | 89.13 | 90.00 | 104.78 | 145.47 | 145.09 | 3.09 | 2.60 | 2.24 | 1.62 | 1.57 | 1.67 | 1.67 |
| Total Assets | 176.32 | 142.12 | 141.70 | 104.78 | 145.47 | 145.09 | 3.09 | 2.60 | 2.24 | 1.62 | 1.57 | 1.67 | 1.67 |
Below is a detailed analysis of the balance sheet data for Gayatri BioOrganics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 78.79 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 78.79 Cr..
- For Reserves, as of Sep 2025, the value is -115.16 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -114.68 Cr. (Mar 2025) to -115.16 Cr., marking a decline of 0.48 Cr..
- For Borrowings, as of Sep 2025, the value is 37.29 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 36.90 Cr. (Mar 2025) to 37.29 Cr., marking an increase of 0.39 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.75 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.66 Cr. (Mar 2025) to 0.75 Cr., marking an increase of 0.09 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1.67 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.67 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1.67 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.67 Cr..
- For Total Assets, as of Sep 2025, the value is 1.67 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.67 Cr..
However, the Borrowings (37.29 Cr.) are higher than the Reserves (-115.16 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -62.60 | -72.81 | -140.31 | -84.32 | -58.97 | -38.72 | -35.72 | -35.61 | -35.61 | -36.43 | -36.89 | -37.35 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 162.69 | 63.12 | 116.05 | 6.95 | 3.18 | 1.22 | 54.64 | |||||
| Inventory Days | 51.08 | 62.87 | 98.30 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Days Payable | 177.53 | 58.80 | 79.17 | |||||||||
| Cash Conversion Cycle | 36.24 | 67.19 | 135.18 | 6.95 | 3.18 | 1.22 | 54.64 | |||||
| Working Capital Days | -18.12 | 5.32 | -103.13 | -365.55 | -212.09 | -271.31 | -7,048.65 | |||||
| ROCE % | 10.65% | 14.68% | -27.28% | -209.87% | -21.01% | -26.53% | -54.61% | -44.54% | -40.72% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Large & Midcap Fund | 452,200 | 0 | 0.8 | 452,200 | 2025-04-22 15:56:50 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -72.65 | -0.09 | -0.13 | -0.06 | -0.06 |
| Diluted EPS (Rs.) | -72.65 | -0.09 | -0.13 | -0.06 | -0.06 |
| Cash EPS (Rs.) | -0.09 | -0.08 | -0.12 | -0.06 | -0.06 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -4.55 | -4.46 | -4.38 | -4.25 | -4.18 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -4.55 | -4.46 | -4.38 | -4.25 | -4.18 |
| Revenue From Operations / Share (Rs.) | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 |
| PBDIT / Share (Rs.) | -0.05 | -0.06 | -0.09 | -0.06 | -0.06 |
| PBIT / Share (Rs.) | -0.05 | -0.06 | -0.09 | -0.06 | -0.06 |
| PBT / Share (Rs.) | -0.09 | -0.08 | -0.10 | -0.06 | -0.06 |
| Net Profit / Share (Rs.) | -0.09 | -0.08 | -0.12 | -0.06 | -0.06 |
| PBDIT Margin (%) | 0.00 | 0.00 | -46.06 | 0.00 | 0.00 |
| PBIT Margin (%) | 0.00 | 0.00 | -46.06 | 0.00 | 0.00 |
| PBT Margin (%) | 0.00 | 0.00 | -47.72 | 0.00 | 0.00 |
| Net Profit Margin (%) | 0.00 | 0.00 | -60.60 | 0.00 | 0.00 |
| Return on Capital Employeed (%) | 1.38 | 1.65 | 2.38 | 1.56 | 1.58 |
| Return On Assets (%) | -43.67 | -43.18 | -62.54 | -22.19 | -19.17 |
| Long Term Debt / Equity (X) | -0.09 | -0.08 | -0.06 | -0.05 | -0.05 |
| Total Debt / Equity (X) | -1.03 | -1.03 | -1.03 | -1.05 | -1.06 |
| Asset Turnover Ratio (%) | 0.00 | 0.00 | 0.86 | 0.00 | 0.00 |
| Current Ratio (X) | 0.04 | 0.04 | 0.04 | 0.06 | 0.07 |
| Quick Ratio (X) | 0.04 | 0.04 | 0.04 | 0.06 | 0.07 |
| Interest Coverage Ratio (X) | -1.62 | -3.56 | -27.83 | -1652.67 | -496.40 |
| Interest Coverage Ratio (Post Tax) (X) | -1.62 | -3.56 | -35.61 | -1652.67 | -496.40 |
| Enterprise Value (Cr.) | 90.61 | 75.80 | 92.13 | 182.80 | 85.41 |
| EV / Net Operating Revenue (X) | 0.00 | 0.00 | 55.25 | 0.00 | 0.00 |
| EV / EBITDA (X) | -201.50 | -142.51 | -119.94 | -368.70 | -172.05 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 0.00 | 33.88 | 0.00 | 0.00 |
| Price / BV (X) | -1.50 | -1.12 | -1.64 | -4.41 | -1.54 |
| Price / Net Operating Revenue (X) | 0.00 | 0.00 | 33.98 | 0.00 | 0.00 |
| EarningsYield | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 |
After reviewing the key financial ratios for Gayatri BioOrganics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -72.65. This value is below the healthy minimum of 5. It has decreased from -0.09 (Mar 24) to -72.65, marking a decrease of 72.56.
- For Diluted EPS (Rs.), as of Mar 25, the value is -72.65. This value is below the healthy minimum of 5. It has decreased from -0.09 (Mar 24) to -72.65, marking a decrease of 72.56.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 3. It has decreased from -0.08 (Mar 24) to -0.09, marking a decrease of 0.01.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -4.55. It has decreased from -4.46 (Mar 24) to -4.55, marking a decrease of 0.09.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -4.55. It has decreased from -4.46 (Mar 24) to -4.55, marking a decrease of 0.09.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.05. This value is below the healthy minimum of 2. It has increased from -0.06 (Mar 24) to -0.05, marking an increase of 0.01.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.05. This value is below the healthy minimum of 0. It has increased from -0.06 (Mar 24) to -0.05, marking an increase of 0.01.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 0. It has decreased from -0.08 (Mar 24) to -0.09, marking a decrease of 0.01.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 2. It has decreased from -0.08 (Mar 24) to -0.09, marking a decrease of 0.01.
- For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Net Profit Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Capital Employeed (%), as of Mar 25, the value is 1.38. This value is below the healthy minimum of 10. It has decreased from 1.65 (Mar 24) to 1.38, marking a decrease of 0.27.
- For Return On Assets (%), as of Mar 25, the value is -43.67. This value is below the healthy minimum of 5. It has decreased from -43.18 (Mar 24) to -43.67, marking a decrease of 0.49.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 0.2. It has decreased from -0.08 (Mar 24) to -0.09, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is -1.03. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded -1.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Current Ratio (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 1.5. There is no change compared to the previous period (Mar 24) which recorded 0.04.
- For Quick Ratio (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.04.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -1.62. This value is below the healthy minimum of 3. It has increased from -3.56 (Mar 24) to -1.62, marking an increase of 1.94.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -1.62. This value is below the healthy minimum of 3. It has increased from -3.56 (Mar 24) to -1.62, marking an increase of 1.94.
- For Enterprise Value (Cr.), as of Mar 25, the value is 90.61. It has increased from 75.80 (Mar 24) to 90.61, marking an increase of 14.81.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / EBITDA (X), as of Mar 25, the value is -201.50. This value is below the healthy minimum of 5. It has decreased from -142.51 (Mar 24) to -201.50, marking a decrease of 58.99.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is -1.50. This value is below the healthy minimum of 1. It has decreased from -1.12 (Mar 24) to -1.50, marking a decrease of 0.38.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded -0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gayatri BioOrganics Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 1.38% (Industry Average ROCE: 40.7%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 0%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -1.62
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.04
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 0)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -1.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Organic - Cellulose Derivatives | B3, 3rd Floor, 6-3-1090, Rajbhavan Road, Hyderabad Telangana 500082 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. T V Sandeep Kumar Reddy | Chairman & Non-Exe.Director |
| Mr. K Sreedhara Reddy | Whole Time Director |
| Mrs. Meenakshi Ramchand Sachdeva | Independent Director |
| Mr. P V Narayana Rao | Independent Director |
| Mr. Srinivas Iduri | Independent Director |
FAQ
What is the intrinsic value of Gayatri BioOrganics Ltd?
Gayatri BioOrganics Ltd's intrinsic value (as of 10 February 2026) is ₹8.41 which is 41.19% lower the current market price of ₹14.30, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹113 Cr. market cap, FY2025-2026 high/low of ₹20.0/5.35, reserves of ₹-115.16 Cr, and liabilities of ₹1.67 Cr.
What is the Market Cap of Gayatri BioOrganics Ltd?
The Market Cap of Gayatri BioOrganics Ltd is 113 Cr..
What is the current Stock Price of Gayatri BioOrganics Ltd as on 10 February 2026?
The current stock price of Gayatri BioOrganics Ltd as on 10 February 2026 is ₹14.3.
What is the High / Low of Gayatri BioOrganics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gayatri BioOrganics Ltd stocks is ₹20.0/5.35.
What is the Stock P/E of Gayatri BioOrganics Ltd?
The Stock P/E of Gayatri BioOrganics Ltd is .
What is the Book Value of Gayatri BioOrganics Ltd?
The Book Value of Gayatri BioOrganics Ltd is 4.62.
What is the Dividend Yield of Gayatri BioOrganics Ltd?
The Dividend Yield of Gayatri BioOrganics Ltd is 0.00 %.
What is the ROCE of Gayatri BioOrganics Ltd?
The ROCE of Gayatri BioOrganics Ltd is 40.7 %.
What is the ROE of Gayatri BioOrganics Ltd?
The ROE of Gayatri BioOrganics Ltd is %.
What is the Face Value of Gayatri BioOrganics Ltd?
The Face Value of Gayatri BioOrganics Ltd is 10.0.